| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/22/2004 | WO2004033405A1 Alkoxylates exhibiting low residual alcohol content |
| 04/22/2004 | WO2004032974A1 Process for generating multilayered particles |
| 04/22/2004 | WO2004032972A1 An oral formulation of methylglyoxal and its imino acid conjugates for human use |
| 04/22/2004 | WO2004032971A1 Pharmaceutically active oligosaccharide conjugates |
| 04/22/2004 | WO2004032970A2 Carriers attached to blood cells |
| 04/22/2004 | WO2004032963A2 Photokinetic delivery of biologically active substances using pulsed incoherent light |
| 04/22/2004 | WO2004032945A1 Active ingredient combinations of polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride and preparations comprising said active ingredient combinations |
| 04/22/2004 | WO2004032944A1 Composition for treating hemorrhoids |
| 04/22/2004 | WO2004032926A1 Gelled laxative compositions |
| 04/22/2004 | WO2004032920A1 Stabilized pharmaceutical preparation comprising an amorphous active substance |
| 04/22/2004 | WO2004032904A1 Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate |
| 04/22/2004 | WO2004032900A1 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| 04/22/2004 | WO2004032898A2 Controlled release system containing sucrose acetate isobutyrate |
| 04/22/2004 | WO2004032866A2 Therapeutic formulations |
| 04/22/2004 | WO2004032863A2 Oral formulations for proteins and polypeptides |
| 04/22/2004 | WO2004032862A2 Cyclodextrin-based materials, compositions and uses related thereto |
| 04/22/2004 | WO2004032859A2 Water soluble sheet composition |
| 04/22/2004 | WO2004032858A2 Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics |
| 04/22/2004 | WO2004032849A2 Methods of administering fgf18 |
| 04/22/2004 | WO2004032843A2 Mucoadhesive tetracycline formulations |
| 04/22/2004 | WO2004032829A2 Immunostimulatory compositions and methods of stimulating an immune response |
| 04/22/2004 | WO2004032828A2 Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| 04/22/2004 | WO2004022657A8 Increasing of the resorption of substances via skin and mucous membranes |
| 04/22/2004 | WO2004022105A3 Preparation of m(co)3-complexes by solid phase techniques via metal assisted cleavage from the solid support |
| 04/22/2004 | WO2004019758A3 Methods of treating idiopathic pulmonary fibrosis |
| 04/22/2004 | WO2004014156A3 A chemical carrier based on a beta-limit dextrin |
| 04/22/2004 | WO2004007557A3 Tf antagonist |
| 04/22/2004 | WO2004000372A3 Disinfecting composition, cleaning tablet produced therefrom, and use thereof |
| 04/22/2004 | WO2003105907A3 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases |
| 04/22/2004 | WO2003105906A8 A process for the preparation of piroxicam: b-cyclodextrin inclusion compounds |
| 04/22/2004 | WO2003103596A8 Stabilized nanoparticle formulations of camptotheca derivatives |
| 04/22/2004 | WO2003103594A3 Micelle assemblies |
| 04/22/2004 | WO2003086286A3 Treatment of type 1 diabetes before and after expression of predisposition markers |
| 04/22/2004 | WO2003063842A9 Composition for inhalation |
| 04/22/2004 | WO2003051300A8 Metal complexes and formulations of rifamycin analogues and uses therof |
| 04/22/2004 | WO2003051299A8 Sulfhydryl rifamycins and uses thereof |
| 04/22/2004 | WO2003041686A3 Improved therapy for topical diseases |
| 04/22/2004 | WO2003026563A9 Conjugated anti-psychotic drugs and uses thereof |
| 04/22/2004 | WO2003020763A9 Soluble t cell receptor |
| 04/22/2004 | WO2003015809A9 Antimicrobial cationic peptides and formulations thereof |
| 04/22/2004 | WO2002092782A3 Diagnosis and treatment of malignant neoplasms |
| 04/22/2004 | WO2002058624A9 In situ generation allicin for the treatment of cancer and infectious diseases |
| 04/22/2004 | US20040077843 Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
| 04/22/2004 | US20040077780 Thermogelling oligopeptide polymers |
| 04/22/2004 | US20040077748 Antibacterial and fungicidal polymer dispersions and polymer solutions |
| 04/22/2004 | US20040077735 Gels comprising hydrophilic nonionic surfactants, aliphatic alcohol, water, and oils, used as topical ointments or cosmetics |
| 04/22/2004 | US20040077724 Compositions comprising an o/w emulsion containing conjugated linoleic acid |
| 04/22/2004 | US20040077719 Food supplements, feed additives, dietetic, cosmetics |
| 04/22/2004 | US20040077708 Atorvastatin calcium; bioavailability |
| 04/22/2004 | US20040077684 Piperidinyl compounds that selectively bind integrins |
| 04/22/2004 | US20040077615 Novel formulations for administering therapeutic lipophilic molecules |
| 04/22/2004 | US20040077612 Acting as prodrugs; higher concentration delivery of active material to target cell in hybrid form; decreasing side effects |
| 04/22/2004 | US20040077604 Reducing toxicity of nonsteroidal antiinflammatory drugs (NSAIDs) |
| 04/22/2004 | US20040077603 Synthetic tear fluid |
| 04/22/2004 | US20040077595 Cyclodextrin-based polymers for therapeutics delivery |
| 04/22/2004 | US20040077594 Included in cyclodextrin derivative; reducing irritation at intramuscular injection site |
| 04/22/2004 | US20040077592 Cross-linked polysaccharide drug carrier |
| 04/22/2004 | US20040077582 Cationic reagents for transfection |
| 04/22/2004 | US20040077562 Corticosteroid and quinolone or amino-glycoside derivative; post operative ophthalmic treatment |
| 04/22/2004 | US20040077560 Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| 04/22/2004 | US20040077559 Doxorubicin hydrochloride acidic solution which has not been reconstituted from lyophilizate |
| 04/22/2004 | US20040077543 Treatment using neublastin polypeptides |
| 04/22/2004 | US20040077541 Methods of using non-human animal Apolipoprotein A-I protein |
| 04/22/2004 | US20040077540 Permeabilizing peptide; reversibly enhancing paracellular transport; inhibits homotypic binding |
| 04/22/2004 | US20040077533 Methods and compositions for treating bacterial infections and diseases associated therewith |
| 04/22/2004 | US20040077528 Entrapping active agent in fumaryl diketopiperazine derivative and solvent washing out impurities; purified insulin for pulmonary administration |
| 04/22/2004 | US20040077232 Pharmaceutical compositions |
| 04/22/2004 | US20040077081 G250 antibodies are capable of eliciting a delayed immune response in cancer therapy, in the treatment of renal cell carcinoma and for the treatment of metastases after tumor surgery |
| 04/22/2004 | US20040077022 Modified peptides as therapeutic agents |
| 04/22/2004 | US20040076991 Modified interleukin-1 receptor antagonist(il-1ra) with reduced immunogenicity |
| 04/22/2004 | US20040076695 EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
| 04/22/2004 | US20040076681 Hollow tubular body comprising and second ends, wherein first end is open, end cap positioned over first open end, end cap attached to hollow tubular body by covalent bond and particle has maximum dimension of less than 100 mu m; drug delivery |
| 04/22/2004 | US20040076680 Obtained by means of physico-chemical crosslinking of the derivatives of high-molecular-weight hyaluronic acid or salts thereof; antiarthritic agents |
| 04/22/2004 | US20040076679 Gel delivery vehicles for anticellular proliferative agents |
| 04/22/2004 | US20040076678 Opthalmic solution |
| 04/22/2004 | US20040076676 Heat-melting polylactic acid having a weight-average molecular weight of 3,000-40,000 at 140-220 degrees C, cooling, pulverizing solidified polylactic acid, adding active materials, compressing powder in mold |
| 04/22/2004 | US20040076673 Oral pharmaceutical composition containing a block copolymer |
| 04/22/2004 | US20040076672 For treating cancer and other angiogenic-dependent diseases, and more specifically, to compositions comprising anti-angiogenic factors and polymeric carriers, stents which have been coated with such compositions |
| 04/22/2004 | US20040076671 Methods and compositions for topical wound treatment |
| 04/22/2004 | US20040076667 Sustained release pharmaceutical composition containing metformin hydrochloride |
| 04/22/2004 | US20040076666 Fast-dispersing dosage forms containing fish gelatin |
| 04/22/2004 | US20040076658 Readily dispersible dietary fiber composition |
| 04/22/2004 | US20040076654 Longer chain length alcohol; odorless |
| 04/22/2004 | US20040076651 Degree of foam-up after storage in a container of at least one week at room temperature is </= 10% |
| 04/22/2004 | US20040076648 Antidepressant, an n-methyl-aspartic acid receptor antagonist, a lipophilic component, water and a surfacant; oil in water emulsion |
| 04/22/2004 | US20040076645 Ghrelin-carrier conjugates |
| 04/22/2004 | US20040076629 Polypeptide with 46 kDalton HMFG differentiation antigen binding specificity and clotting factors V and VIII light-chain homologies, fusion protein, polynucleotide and polyribonucleotide encoding the polypeptide, anti-polypeptide antibodies, kits and methods of use thereof |
| 04/22/2004 | US20040076602 Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
| 04/22/2004 | US20040076599 Keratin-based powders and hydrogel for pharmaceutical applications |
| 04/22/2004 | US20040076598 For moisturizing skin and/or mucous membranes; for treating hair/eyes |
| 04/22/2004 | US20040076586 For administration to tissues/mononuclear phagocytes/ macrophages; for treatment of inflammatory diseases/disorders |
| 04/22/2004 | US20040076585 Nanoparticles of cyclic tetrapyrrolic compounds as gene and drug delivery carriers |
| 04/22/2004 | US20040074503 Urine incontinenece device and corresponding method |
| 04/22/2004 | DE10247755A1 New fusion polypeptide, useful for treating e.g. cancer, infections and inflammation, comprises binding domain for cell-surface molecule and fragment of tumor necrosis factor ligand |
| 04/22/2004 | DE10085492T5 Antimonocytenaktivität von extrakten von Betelpfefferblättern Antimonocytenaktivität of extracts of Betelpfefferblättern |
| 04/22/2004 | CA2782847A1 Methods of administering fgf18 |
| 04/22/2004 | CA2501970A1 Gelled laxative compositions |
| 04/22/2004 | CA2501614A1 Mucoadhesive tetracycline formulations |
| 04/22/2004 | CA2501133A1 Oral formulations for proteins and polypeptides |
| 04/22/2004 | CA2501132A1 Cyclodextrin-based materials, compositions and uses related thereto |